Literature DB >> 25130212

A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.

S E K Fink1, M K Gandhi, J P Nourse, C Keane, K Jones, P Crooks, K Jöhrens, A Korfel, H Schmidt, S Neumann, A Tiede, U Jäger, U Dührsen, R Neuhaus, M Dreyling, K Borchert, T Südhoff, H Riess, I Anagnostopoulos, R U Trappe.   

Abstract

Primary central nervous system (pCNS) posttransplant lymphoproliferative disorder (PTLD) is a complication of solid organ transplantation characterized by poor outcome. In contrast to systemic PTLD, Epstein-Barr virus (EBV)-association of pCNS PTLD is almost universal, yet viral and cellular data are limited. To identify differences in the pattern of EBV-association of pCNS and systemic PTLD, we analyzed the expression of latent and lytic EBV transcripts and the viral and cellular microRNAome in nine pCNS (eight EBV-associated) and in 16 systemic PTLD samples (eight EBV-associated). Notably although 15/16 EBV-associated samples exhibited a viral type III latency pattern, lytic transcripts were also strongly expressed. Members of the ebv-miR-BHRF1 and ebv-miR-BART clusters were expressed in virtually all EBV-associated PTLD samples. There were 28 cellular microRNAs differentially expressed between systemic and pCNS PTLD. pCNS PTLD expressed lower hsa-miR-199a-5p/3p and hsa-miR-143/145 (implicated in nuclear factor kappa beta and c-myc signaling) as compared to systemic PTLD. Unsupervised nonhierarchical clustering of the viral and cellular microRNAome distinguished non-EBV-associated from EBV-associated samples and identified a separate group of EBV-associated pCNS PTLD that displayed reduced levels of B cell lymphoma associated oncomiRs such as hsa-miR-155, -21, -221 and the hsa-miR-17-92 cluster. EBV has a major impact on viral and cellular microRNA expression in EBV-associated pCNS PTLD. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Kidney transplantation/nephrology; molecular biology: micro RNA; posttransplant lymphoproliferative disorder (PTLD); translational research/science

Mesh:

Substances:

Year:  2014        PMID: 25130212     DOI: 10.1111/ajt.12858

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  21 in total

1.  Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.

Authors:  Heiner Zimmermann; Mirko Nitsche; Christiane Pott; Petra Reinke; Nina Babel; Robert M Hermann; Ingeborg A Hauser; Dennis Hahn; Matthias Ritgen; Claudia Pietschmann; Wolfram Klapper; Ioannis Anagnostopoulos; Ralf U Trappe
Journal:  Ann Hematol       Date:  2021-05-11       Impact factor: 3.673

2.  Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.

Authors:  Eckart Meese; Friedrich A Grässer; Hiresh Ayoubian; Nicole Ludwig; Tobias Fehlmann; Jennifer Menegatti; Laura Gröger; Eleni Anastasiadou; Pankaj Trivedi; Andreas Keller
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 3.  A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types.

Authors:  Saber Soltani; Armin Zakeri; Alireza Tabibzadeh; Amir Mohammad Zakeri; Milad Zandi; Saba Siavoshi; Saba Seifpour; Abbas Farahani
Journal:  Mol Biol Rep       Date:  2021-02-01       Impact factor: 2.316

4.  EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.

Authors:  Alexandre S Cristino; Jamie Nourse; Rachael A West; Muhammed Bilal Sabdia; Soi C Law; Jay Gunawardana; Frank Vari; Sally Mujaj; Gayathri Thillaiyampalam; Cameron Snell; Madeline Gough; Colm Keane; Maher K Gandhi
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

5.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

Review 6.  Role of microRNAs in primary central nervous system lymphomas.

Authors:  Xin Yu; Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-03-16       Impact factor: 6.831

7.  Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.

Authors:  James P Dugan; Bradley M Haverkos; Lynda Villagomez; Ludmila K Martin; Mark Lustberg; John Patton; Marisa Martin; Ying Huang; Gerard Nuovo; Fengting Yan; Robert Cavaliere; Joyce Fingeroth; Shannon C Kenney; Richard F Ambinder; Gerard Lozanski; Pierluigi Porcu; Michael A Caligiuri; Robert A Baiocchi
Journal:  Clin Cancer Res       Date:  2018-04-09       Impact factor: 12.531

Review 8.  Deletion of Viral microRNAs in the Oncogenesis of Epstein-Barr Virus-Associated Lymphoma.

Authors:  Hiroshi Kimura; Yusuke Okuno; Yoshitaka Sato; Takahiro Watanabe; Takayuki Murata
Journal:  Front Microbiol       Date:  2021-07-08       Impact factor: 5.640

9.  Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.

Authors:  Genevieve M Crane; Helen Powell; Rumen Kostadinov; Patrick Tim Rocafort; Dena E Rifkin; Peter C Burger; Richard F Ambinder; Lode J Swinnen; Michael J Borowitz; Amy S Duffield
Journal:  Oncotarget       Date:  2015-10-20

Review 10.  Epstein-Barr Virus: Diseases Linked to Infection and Transformation.

Authors:  Hem C Jha; Yonggang Pei; Erle S Robertson
Journal:  Front Microbiol       Date:  2016-10-25       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.